+874 (T--&gt;A) single nucleotide gene polymorphism does not represent a risk factor for Alzheimer&apos;s disease by L. Galimberti et al.
BioMed CentralImmunity & Ageing
ssOpen AcceShort report
+874(T→A) single nucleotide gene polymorphism does not 
represent a risk factor for Alzheimer's disease
Lorenza Galimberti1, Beatrice Arosio1, Carmen Calabresi1, Silvia Scurati1, 
Susanna Hamilton1, Simona Delli Carpini1, Carlo Vergani1 and 
Giorgio Annoni*2
Address: 1Department of Geriatrics, Ospedale Maggiore IRCCS, University of Milano, Milan, Italy and 2Department of Clinical Medicine, 
Prevention and Medical Biotechnology, University of Milano-Bicocca, Mila, Italy
Email: Lorenza Galimberti - geriatri@policlinico.mi.it; Beatrice Arosio - geriatri@policlinico.mi.it; Carmen Calabresi - geriatri@policlinico.mi.it; 
Silvia Scurati - geriatri@policlinico.mi.it; Susanna Hamilton - geriatri@policlinico.mi.it; Simona Delli Carpini - geriatri@policlinico.mi.it; 
Carlo Vergani - erice1947@hotmail.com; Giorgio Annoni* - giorgio.annoni@unimib.it
* Corresponding author    
Abstract
In the recent years, several cytokines have been associated with Alzheimer's disease (AD)
development and progression and many studies have correlated this risk with polymorphisms in
the genes encoding these molecules. Also the type 1 cytokine interferon (IFN)-γ belongs to a
cytokine class that affects the immune function; in fact it plays a major role in defence against viruses
and intracellular pathogens but also in the induction of the immune-mediated inflammatory
response. The aim of this study was to evaluate the role of IFN-γ in AD by studying the association
of +874T→A IFN-γ gene polymorphism with AD. We included in this study 115 AD patients (70
women, 45 men, mean age 80) and 90 sex and age-matched healthy controls (HC, 51 women, 39
men, mean age 82) from northern Italy. Genomic DNA was extracted with the salting-out method
from whole blood of all subjects; the genotyping at IFN-γ loci was assessed with ARMS-PCR. The
data obtained from the +874T→A IFN-γ gene polymorphism analysis of AD patients and HC lack
of any statistically significant differences also when stratified according to gender. In conclusion
these results confirm the previous shown lack of association between +874T→A IFN-γ gene
polymorphism and the risk of AD. However, other polymorphisms have been demonstrated to
influence IFN-γ transcription and since natural killer cells of AD patients show higher production
of the cytokine, further analysis will be necessary to clarify the role of this gene in the pathogenesis
of the disease.
In the human brain several cell types are responsible for
initiating and amplifying a specific inflammatory
response. In Alzheimer disease (AD) signs of an inflam-
matory activation of microglia and astroglia are present
both inside and outside amyloid deposits. Cell cultures
and animal models suggest an interactive relationship
between inflammatory response activation, reduced neu-
ronal functioning and amyloid deposition. Furthermore
cells associated with extracellular plaques within AD
brains can produce a variety of cytokines, chemokines and
other related proteins that influence plaque and tangle
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critical role in the pathogenesis of AD. In the recent years,
several cytokines have been associated with AD develop-
ment and progression and many studies have correlated
this risk with polymorphisms in the genes encoding these
molecules [2-4]. Inside this research area we described
that single nucleotide polymorphisms (SNP)s of the
intereleukin(IL)-10 and IL-6 genes were associated with
highest risk of AD with apparent interaction between
these two genes [5]; these results supported the theory
that the overall risk of developing AD may be governed by
a 'susceptibility profile' and reflected the combined influ-
ence of inheriting multiple high-risk alleles. Also the type
1 cytokine interferon (IFN)-γ belongs to a cytokine class
that affects the immune function; in fact it plays a major
role in defence against viruses and intracellular pathogens
but also in the induction of the immune-mediated
inflammatory response [6]. It has been reported that the
polymorphism +874(T→A) of the gene encoding IFN-γ is
associated with a different production of this molecule, in
particular the T allele correlates with increased levels of
the cytokine [7]. In regards to the hypothesis that IFN-γ
SNP may represent a genetic risk factor for AD, a recent
study did not support this possibility [8]. Therefore with
reference to this paper we try to confirm their hypothesis
in a sample of patients, that were already genotyped for
apolipoprotein E (ApoE), IL-10 and IL-6 [5]. We included
in this study 115 AD patients (70 women, 45 men, mean
age 80 ± 2) and 90 sex and age-matched healthy controls
(HC, 51 women, 39 men, mean age 82 ± 2) from northern
Italy. The clinical diagnosis of AD fulfilled the interna-
tional criteria of the DMS IV and NINCDS-ADRDA; every
patient had a recent brain magnetic resonance imaging
(MRI)/computed tomography (CT) scan available. Cogni-
tive performances were assessed according to the Mini-
Mental State Evaluation (MMSE). Only AD and HC with-
out clinical signs of inflammation (e.g. normal body tem-
perature, no concomitant inflammatory condition) were
eligible in order to minimize the risk of clinical or sub-
clinical inflammatory processes. Blood chemistry tests
were done and subjects with an abnormal red blood cell
sedimentation rate or altered albumin and transferrin
plasma levels were excluded. AD patients were further
selected according to their C reactive protein (CRP)
plasma levels and anyone with CRP above 5 mg/L (mean
+ 2 standard deviations of control values) were not eligi-
ble. Informed consent was obtained from all the subjects
or their relatives. Genomic DNA was extracted with the
salting-out method from whole blood of all subjects; the
genotyping at IFN-γ loci was assessed with the same
amplification method (ARMS-PCR) described by Scola et
al. [8]. The genotype frequencies in the study groups were
compared by the chi-square (χ) test in order to calculate
significant different SNP distribution between AD
patients and controls (Table 1). The data obtained from
the +874T→A IFN-γ gene polymorphism analysis of AD
patients and HC lack of any statistically significant differ-
ences also when stratified according to gender (data not
shown). The percentage of the different genotypes was
similar in AD compared with HC (T/T: 17.4% vs. 16.8% ;
T/A: 50.4% vs. 55.1% ; A/A 32.2% vs. 28.1%) and conse-
quently also the allele distribution shows no differences
(T: 42.6% vs. 44.4% ; A: 57.4% vs. 55.6%). Our genotype
distribution looks very similar to that found by Scola et al.
[8]. In conclusion these results confirm the lake of associ-
ation between +874T→A IFN-γ gene polymorphism and
the risk of AD. Nevertheless other polymorphisms have
been demonstrated to influence IFN-γ transcription and
since natural killer cells of AD patients show higher pro-
duction of the cytokine, further analysis will be necessary
to clarify the role of this gene in the pathogenesis of the
disease [9,10].
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Table 1: IFN-γ genotype and allele distribution
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